Ethos Cannabis Expands Into Ohio With Cultivation And Dispensary Acquisitions
Previously, Ethos’s footprint included retail and production in MA, PA and MD
Ethos Cannabis has announced its acquisition of two cannabis businesses in the Ohio medical cannabis market. The acquisition of these businesses will further the Ethos footprint westward.
Previously, Ethos’s footprint included retail and production operations in Massachusetts, Pennsylvania and Maryland. This expansion into the Ohio market allows the company to continue advancing its intent to deliver high-quality cannabis to consumers across the United States.
In December 2021, Ethos acquired Agri-Med Ohio, a Tier II Medical Cultivation Licensee located in Langsville. Agri-Med Ohio is being integrated into the Ethos platform to further enhance and expand operations. Ethos will continue to produce the Meigs County line of products and looks forward to introducing additional products to the Ohio market in the future.
In April 2022, Ethos acquired About Wellness Ohio, a medical dispensary licensee located in the Greater Cincinnati Area in Lebanon. In the near-term, the dispensary will continue to operate as About Wellness Ohio but the company plans to transition the dispensary to the Ethos Cannabis brand later in 2022. Ethos is focused on continuing to provide all the positive attributes of the About Wellness Ohio experience, while launching attractive enhancements to continue to improve the patient experience.
“The acquisitions in Ohio position us to continue extending our retail experience and products to benefit more patients. As one of the most populated states in the U.S., Ohio is a natural progression for us as we further expand our operations. We are thrilled to continue leading this industry forward in a manner that puts health and wellness at the forefront,” said David Clapper, Ethos CEO.
Ethos is committed to creating a wellness-oriented cannabis industry. The company has a partnership with Thomas Jefferson University, a leading academic medical center located in Philadelphia, Penn., focused on research programs that are both broad-based and targeted to specific study areas such as anxiety and opioid use.
